87 related articles for article (PubMed ID: 8890564)
1. [Glycosylphosphatidylinositol-anchored proteins with complement-regulatory activity on erythrocytes].
Kawaguchi T; Nakakuma H
Nihon Rinsho; 1996 Sep; 54(9):2370-5. PubMed ID: 8890564
[TBL] [Abstract][Full Text] [Related]
2. Glucose-induced loss of glycosyl-phosphatidylinositol-anchored membrane regulators of complement activation (CD59, CD55) by in vitro cultured human umbilical vein endothelial cells.
Accardo-Palumbo A; Triolo G; Colonna-Romano G; Potestio M; Carbone M; Ferrante A; Giardina E; Caimi G; Triolo G
Diabetologia; 2000 Aug; 43(8):1039-47. PubMed ID: 10990082
[TBL] [Abstract][Full Text] [Related]
3. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.
Miwa T; Zhou L; Hilliard B; Molina H; Song WC
Blood; 2002 May; 99(10):3707-16. PubMed ID: 11986227
[TBL] [Abstract][Full Text] [Related]
4. Test for ability of decay-accelerating factor (DAF, CD55) and CD59 to alleviate complement-mediated damage of xeno-erythrocytes.
Miyagawa S; Shirakura R; Matsumiya G; Nakata S; Matsuda H; Hatanaka M; Matsumoto M; Kitamura H; Seya T
Scand J Immunol; 1993 Jul; 38(1):37-44. PubMed ID: 7687071
[TBL] [Abstract][Full Text] [Related]
5. The effects of marathon running on expression of the complement regulatory proteins CD55 (DAF) and CD59 (MACIF) on red blood cells.
Simpson RJ; Florida-James GD; Whyte GP; Middleton N; Shave R; George K; Guy K
Eur J Appl Physiol; 2007 Jan; 99(2):201-4. PubMed ID: 17089158
[TBL] [Abstract][Full Text] [Related]
6. Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation.
Varsano S; Frolkis I; Rashkovsky L; Ophir D; Fishelson Z
Am J Respir Cell Mol Biol; 1996 Dec; 15(6):731-7. PubMed ID: 8969267
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
[TBL] [Abstract][Full Text] [Related]
8. Impaired expression of erythrocyte glycosyl-phosphatidylinositol-anchored membrane CD59 in patients with psoriatic arthritis. Relation to terminal complement pathway activation.
Triolo G; Accardo-Palumbo A; Sallì L; Ciccia F; Ferrante A; Tedesco L; Sallì S; Giardina E; Pappalardo A; Licata G
Clin Exp Rheumatol; 2003; 21(2):225-8. PubMed ID: 12747280
[TBL] [Abstract][Full Text] [Related]
9. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
Niehans GA; Cherwitz DL; Staley NA; Knapp DJ; Dalmasso AP
Am J Pathol; 1996 Jul; 149(1):129-42. PubMed ID: 8686736
[TBL] [Abstract][Full Text] [Related]
10. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.
Sun X; Funk CD; Deng C; Sahu A; Lambris JD; Song WC
Proc Natl Acad Sci U S A; 1999 Jan; 96(2):628-33. PubMed ID: 9892684
[TBL] [Abstract][Full Text] [Related]
11. Host cell factor CD59 restricts complement lysis of Plasmodium falciparum-infected erythrocytes.
Wiesner J; Jomaa H; Wilhelm M; Tony HP; Kremsner PG; Horrocks P; Lanzer M
Eur J Immunol; 1997 Oct; 27(10):2708-13. PubMed ID: 9368630
[TBL] [Abstract][Full Text] [Related]
12. Enhanced complement susceptibility of avidin-biotin-treated human erythrocytes is a consequence of neutralization of the complement regulators CD59 and decay accelerating factor.
Zaltzman AB; Van den Berg CW; Muzykantov VR; Morgan BP
Biochem J; 1995 May; 307 ( Pt 3)(Pt 3):651-6. PubMed ID: 7537958
[TBL] [Abstract][Full Text] [Related]
13. Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59.
Ratnoff WD; Knez JJ; Prince GM; Okada H; Lachmann PJ; Medof ME
Clin Exp Immunol; 1992 Mar; 87(3):415-21. PubMed ID: 1371955
[TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction.
Saifuddin M; Hedayati T; Atkinson JP; Holguin MH; Parker CJ; Spear GT
J Gen Virol; 1997 Aug; 78 ( Pt 8)():1907-11. PubMed ID: 9266986
[TBL] [Abstract][Full Text] [Related]
15. Complement regulatory proteins in glomerular diseases.
Nangaku M
Kidney Int; 1998 Nov; 54(5):1419-28. PubMed ID: 9844117
[TBL] [Abstract][Full Text] [Related]
16. New monoclonal antibodies in CD59: use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes.
Fletcher A; Bryant JA; Gardner B; Judson PA; Spring FA; Parsons SF; Mallinson G; Anstee DJ
Immunology; 1992 Mar; 75(3):507-12. PubMed ID: 1374058
[TBL] [Abstract][Full Text] [Related]
17. Complement-regulatory protein expression and activation of complement cascade on erythrocytes from patients with rheumatoid arthritis (RA).
Arora M; Kumar A; Das SN; Srivastava LM
Clin Exp Immunol; 1998 Jan; 111(1):102-6. PubMed ID: 9472668
[TBL] [Abstract][Full Text] [Related]
18. The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias.
Ruiz-Argüelles A; Llorente L
Autoimmun Rev; 2007 Jan; 6(3):155-61. PubMed ID: 17289551
[TBL] [Abstract][Full Text] [Related]
19. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor.
Charreau B; Cassard A; Tesson L; Le Mauff B; Navenot JM; Blanchard D; Lublin D; Soulillou JP; Anegon I
Transplantation; 1994 Dec; 58(11):1222-9. PubMed ID: 7527603
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells. An analysis of the functional importance of complement inhibitors on the Raji cell line.
Harris CL; Morgan BP
Immunology; 1995 Oct; 86(2):311-8. PubMed ID: 7490134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
